Worldwide Innovative Networking in personalized cancer medicine WIN Consortium = invites you to the 3rd WIN Symposium • 6th-8th J= uly, 2011 • Palais des Congrès de Paris [France] The 3rd WIN Symposium, E.O.R.T.C. endorsed, brings worldwide pharma, biotech, and academics together to address the rapidly advancing field of personalized cancer me= dicine. WIN announces a unique scientific program (www.winconsortium.org/program ). The WIN Symposium will inaugurate an unprecedented fo= rmat, where pharma, biotech, academia and patient organizations will be giving their views on how to address the chal= lenges of efficacy of cancer diagnostics and therapeutics in the era of personalized healthcare, to the benefit of the pat= ient. = “We aim to create a forum for open discussion i= n which the expertise and input from all stakeholders in targeted cancer drug development are crucial” said Dr. John Mendelsohn, ! ;Chairman of the WIN Consortium and President of the University of Texas MD Anderson Cancer Center. Outstanding speakers will be leading this unique eve= nt: pharma and biotech Mike Burgess, Robert Wasserman and Peter-Ulrich Rohr = (Roche), Gary Gilliland (Merck and Co), Nick Botwood (AstraZeneca), Shannon Morris (GlaxoSmithKline= ), Samit Hirawat (Novartis), Antonella Isacchi and Artur= o Galvani (Nerviano Medical Sciences), Paul Billings and Martin Naley (Life Technologies), Leo Bonilla (Agilent Technologies) and Ian Wilson (GE= Healthcare). academia and patient organizations John Mendelsohn, Razelle Kurzrock and Donald Berry (UT-MD Anderson Cancer Center), Samir Hanash (Fred Hutchinson Cancer Center), Leroy Hood (Institut= for Systems Biology Seattle), David Sidransky (Johns = Hopkins University), Stephen Friend (Sage Bionetworks), Keneth Anderson (Dana Farber Cancer Institute), Alexander Eggermont and Jean-Charles Soria (Institut = Gustave Roussy), Janell! e Hail (National Breast Cancer Foundation), Julio E. Celis (Danish Cancer Society), Denis Lacombe (EORTC), Robert Kerbel (Sunnybrook Health Sciences Center), Dominique Stoppa-Lyonnet (Institut Curie) and many others. Topics addressed: = • Evidence for efficacy of targeted therapeutics= • Improving the efficacy of biomarker-driven clinical trials • Combinations of targeted drugs • Discovering and validating new targets and pre= dictive biomarkers • Advances in technology, bioinformatics and system= s biology • Strategic alliances to fight cancer = “A synthesis of the symposium, will be presente= d by Dr. Richard L. Schilsky, Chairman of the WIN Scientific Advisory Board, aiming to present concrete perspectives to improve cl= inical outcomes and the quality of life for cancer patients worldwide” says Vladimir Lazar, WIN Chief Operating Officer Register now on http://www.winconsortium.org Contacts Vladimir ! Lazar, Chief Operating Officer: vladimir.lazar@igr= .fr Tel: +33 14! 2 11 40 20 Catherine Bresson, Director of Operational Team: catherine.bres...@winconsortium.org To unsubscribe or change your subscription options, please contact: newsletterWIN
